Advertisement

Huisarts en Wetenschap

, Volume 52, Issue 6, pp 289–296 | Cite as

Dosisverhoging SSRI’s bij depressie is niet zinvol

  • Eric Ruhé
  • Jan Booij
  • Henk van Weert
  • Johannes Reitsma
  • Eric Franssen
  • Martin Michel
  • Aart Schene
Beschouwing

Samenvatting

Ruhé HG, Booij J, Van Weert HC, Reitsma JB, Franssen EJF, Michel MC, Schene AH. Dosisverhoging SSRI’s bij depressie is niet zinvol. Huisarts Wet 2009;52(6):289-96.

Achtergrond Depressieve patiënten die niet genoeg baat hebben bij een standaarddosering selectieve serotonineheropnameremmers (SSRI’s) krijgen vaak een hogere dosis voorgeschreven. In deze wetenschappelijke beschouwing becommentariëren we de werkzaamheid van deze strategie.

Methode We deden een systematisch literatuuronderzoek in vier databases naar gerandomiseerde, gecontroleerde onderzoeken en meta-analyses. Daarnaast voerden we een gerandomiseerd, placebogecontroleerd dosisverhogingsonderzoek uit bij unipolair depressieve patiënten van 18 tot 70 jaar (Hamilton Depression Rating Scale (HDRS17) > 18), met randomisatie (T0) van non-responders (HDRS17 daling < 50%; n= 60) na 6 weken paroxetine (20 mg/dag) naar dubbelblind verstrekte paroxetineverhoging (30-50 mg/dag) of placeboverhoging (paroxetine 20 mg/dag + placebo). De follow-up duurde zes weken (T1). We maakten op drie momenten serotonine-transporter (SERT) SPECT-scans: bij medicatievrije patiënten voorafgaand aan de behandeling, na zes weken behandeling met een standaarddosering en weer zes weken later na dosisverhoging. 
Resultaten De zeven dosisverhogingsonderzoeken en drie meta-analyses/beschouwingen die wij vonden, gaven geen eenduidige ondersteuning voor dosisverhoging. Wij staakten ons dosisverhogingsonderzoek na een interim-analyse (a priori stopregel voor futiliteit: p > 0,5). Van de 30 non-responders met paroxetineverhoging (46,7 ±5,5 mg/dag) reageerden er 10 (33,3%) alsnog op de dosisverhoging; datzelfde gold voor 10 van de 27 (37,0%) non-responders met placeboverhoging (p=0,788). Gedurende de follow-up was er geen significant effect van de dosisverhoging (p = 0,88). SPECT-scans toonden geen significante toename van de SERT-bezetting van het ‘midbrain’ (2,5 ±26,4% paroxetineverhoging; 3,1 ±25,8% placeboverhoging; p = 0,687) of het ‘diencephalon’ (p = 0,529).

Conclusie Dosisverhoging van SSRI’s bij depressieve patiënten is niet werkzaam omdat de hogere dosering niet leidt tot een significante toename van de SERT-bezetting.

beschouwing depressie antidepressiva therapie 

Literatuur

  1. 1.
    Stichting Farmaceutische Kengetallen. Data en feiten 2007. Den Haag, Stichting Farmaceutische Kengetallen.Google Scholar
  2. 2.
    Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46 S1:38S-58S.Google Scholar
  3. 3.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000;157:1-45.Google Scholar
  4. 4.
    Van Marwijk HW, Grundmeijer HG, Bijl D, Van Gelderen MG, De Haan M, Van Weel-Baumgarten EM, et al. NHG-Standaard Depressieve stoornis (eerste herziening). Huisarts Wet 2003;46:614-23.Google Scholar
  5. 5.
    Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836-55.Google Scholar
  6. 6.
    Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003;160:734-40.Google Scholar
  7. 7.
    Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53 Sl:21-6.Google Scholar
  8. 8.
    Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387-400.Google Scholar
  9. 9.
    Ruhé HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: Systematic review. Br J Psychiatry 2006;189:309-16.Google Scholar
  10. 10.
    Ruhé HG, Huyser J, Swinkels JA, Schene AH. Wat te doen als de eerste pil niet werkt? Een Evidence-Based richtlijn voor de biologische behandeling van depressie bij onvoldoende respons op een standaarddosering van een eerste SSRI. Amsterdam, Zorgprogramma Stemmingsstoornissen MFO Psychiatrie AMC/De Meren, 2002.Google Scholar
  11. 11.
    Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-9.Google Scholar
  12. 12.
    Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11.Google Scholar
  13. 13.
    Benkert O, Szegedi A, Wetzel H, Staab HJ, Meister W, Philipp M. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 1997;95:288-96.Google Scholar
  14. 14.
    Schweizer E, Rynn M, Mandos LA, DeMartinis N, Garcia-Espana F, Rickels K. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001;16:137-43.Google Scholar
  15. 15.
    Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002;161:143-51.Google Scholar
  16. 16.
    Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-4.Google Scholar
  17. 17.
    Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-87.Google Scholar
  18. 18.
    Baker CB, Tweedie R, Duval S, Woods SW. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9.Google Scholar
  19. 19.
    Corruble E, Guelfi JD. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand 2000;101:343-8.Google Scholar
  20. 20.
    Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999;174:297-303.Google Scholar
  21. 21.
    Ruhé HG, Booij J, Van Weert HC, Reitsma JB, Franssen EJF, Michel MC, et al. Evidence why dose-escalation of paroxetine in major depressive disorder is not effective: A 6-week, randomized-controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology 2009;34:999-1010.Google Scholar
  22. 22.
    GlaxoSmithKline. Paxil® Prescribing information and medication guide PXL:47PI (available at http://us.gsk.com/products/assets/us_paxil.pdf). 2008;1-44. Research Triangle Park, North Carolina. Google Scholar
  23. 23.
    First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders Patient Edition (SCID-I/P version 2.0). Nederlandse vertaling: Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA. Lisse, the Netherlands, Swets & Zeitlinger, 1999.Google Scholar
  24. 24.
    Ruhé HG, Dekker JJ, Peen J, Holman R, de Jonghe F. Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005;46:417-27.Google Scholar
  25. 25.
    Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996;26:477-86.Google Scholar
  26. 26.
    De Win MM, Habraken JB, Reneman L, Van den Brink W, Den Heeten GJ, Booij J. Validation of [123I]β-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005;30:996-1005.Google Scholar
  27. 27.
    O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.Google Scholar
  28. 28.
    Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram--a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9 S1:35-40.Google Scholar
  29. 29.
    Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6.Google Scholar
  30. 30.
    Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006;39:128-34.Google Scholar
  31. 31.
    Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987;23:164-8.Google Scholar
  32. 32.
    Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988;24:183-8.Google Scholar
  33. 33.
    Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996;8:139-51.Google Scholar
  34. 34.
    Amin M, Lehmann H, Mirmiran J. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 1989;25:164-7.Google Scholar
  35. 35.
    Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602.Google Scholar
  36. 36.
    Guy W, Manov G, Wilson WH. Double-blind dose determination study of a new antidepressant Sertraline. Drug Development Research 1986;9:267-72.Google Scholar
  37. 37.
    Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2007;1-8.Google Scholar
  38. 38.
    Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006;26:250-8.Google Scholar
  39. 39.
    Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998;59:116-22.Google Scholar
  40. 40.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70.Google Scholar
  41. 41.
    Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006;185:395-9.Google Scholar
  42. 42.
    Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-92.Google Scholar
  43. 43.
    Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography Study. Am J Psychiatry 2004;161:826-35.Google Scholar
  44. 44.
    Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32:86-102.Google Scholar
  45. 45.
    Kent JM, Coplan JD, Lombardo I, Hwang DR, Huang Y, Mawlawi O, et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652. Psychopharmacology (Berl) 2002;164:341-8.Google Scholar
  46. 46.
    Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry 2001;158:1843-9.Google Scholar
  47. 47.
    Parsey RV, Kent JM, Oquendo MA, Richards MC, Pratap M, Cooper TB, et al. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry 2006;59:821-8.Google Scholar
  48. 48.
    Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386-91.Google Scholar
  49. 49.
    Catafau AM, Perez V, Plaza P, Pascual JC, Bullich S, Suarez M, et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a [123I]-ADAM SPECT study. Psychopharmacology (Berl) 2006;189:145-53.Google Scholar
  50. 50.
    Herold N, Uebelhack K, Franke L, Amthauer H, Luedemann L, Bruhn H, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM. J Neural Transm 2006;113:659-70.Google Scholar
  51. 51.
    Ruhé HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F, et al. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 2009;19:67-76.Google Scholar
  52. 52.
    Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, et al. N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4'-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-8.Google Scholar
  53. 53.
    Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.Google Scholar
  54. 54.
    Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-6.Google Scholar
  55. 55.
    Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008;33:73-83.Google Scholar
  56. 56.
    Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999;19:10494-501.Google Scholar
  57. 57.
    Djavadian RL. Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals. Acta Neurobiol Exp (Wars) 2004;64:189-200.Google Scholar
  58. 58.
    Davidson C, Stamford JA. Effect of chronic paroxetine treatment on 5-HT1B and 5-HT1D autoreceptors in rat dorsal raphe nucleus. Neurochem Int 2000;36:91-6.Google Scholar
  59. 59.
    Van der Velde V (red). Richtlijn voor de multidisciplinaire diagnostiek, behandeling en begeleiding van volwassen cliënten met een angststoornis. Utrecht: Trimbos-instituut, 2003; in opdracht van de Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ.Google Scholar
  60. 60.
    Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006;29:553-84, xi.Google Scholar
  61. 61.
    Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67:15-22.Google Scholar

Copyright information

© Bohn Stafleu van Loghum 2009

Authors and Affiliations

  • Eric Ruhé
    • 1
  • Jan Booij
  • Henk van Weert
  • Johannes Reitsma
  • Eric Franssen
  • Martin Michel
  • Aart Schene
  1. 1.

Personalised recommendations